10

25


CLAIMS

An anti-inflammatory agent which affects by way of a TNF- α inhibitory action and comprises a compound of the formula:

$$R - (Y)_{m} - (CH_{2})_{n} - CH_{0} \qquad E \qquad A - CH - CH_{0} \qquad C = 0$$

wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula -CO-, -CH(OH)-, or -NR³- where R³ represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R¹ represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R¹; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof.

- 2. An anti-inflammatory agent according to Claim 1, wherein the heterocyclic group represented by R is a 5- to 7-membered monocyclic and heterocyclic group containing 1 to 4 hetero-atoms selected from oxygen, sulfur and nitrogen in addition to carbon as ring members or a condensed heterocyclic group.
- 3. An anti-inflammatory agent according to Claim 1,
 30 wherein R represents a heterocyclic group that may be substituted.
 - 4. An anti-inflammatory agent according to Claim 3, wherein the heterocyclic group is pyridyl, oxazolyl or thiazolyl.
- 35 5. An anti-inflammatory agent according to Claim 1, wherein the partial structural formula:



- 5 6. An anti-inflammatory agent according to Claim 1, wherein X represents CH.
 - 7. An anti-inflammatory agent according to Claim 1, wherein R¹ represents hydrogen.
 - 8. An anti-inflammatory agent according to Claim 1,
- 10 wherein L and M respectively represent hydrogen.
 - 9. An anti-inflammatory agent according to Claim 1, wherein the compound is 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione.
 - 10. An anti-inflammatory agent according to Claim 1,
- wherein the compound is (R)-(+)-5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-oxazolidinedione.
- Method for treating or preventing a TNF-α mediated inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound as defined in claim 1 or a pharmacologically acceptable, salt thereof.
 - 12. Use of a compound as defined in claim 1 or a pharmacologically acceptable salt thereof for the
- 25 manufacture of an agent for prophylaxis or treatment of a TNF- α mediated inflammatory disease.

